lotiglipron + rosuvastatin

Lotiglipron + rosuvastatin refers to the co-administration of two pharmaceutical agents for clinical pharmacology or potential therapeutic purposes. Lotiglipron (PF-07081532) is a once-daily, oral small-molecule glucagon-like peptide-1 receptor agonist developed for obesity and type 2 diabetes. It acts by enhancing glucose-dependent insulin secretion, slowing gastric emptying, and promoting satiety, which aids in glycemic control and weight loss. Rosuvastatin is a potent oral statin used for lowering LDL cholesterol and preventing cardiovascular disease by inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. The combination was studied in healthy overweight or obese adults to assess drug-drug interactions, showing that coadministration raised rosuvastatin exposure and was associated with increased liver enzyme elevations. The development of lotiglipron was terminated due to safety concerns including liver enzyme abnormalities[1][3][4].